- Live Vaccines
- Attenuated Vaccines
Shingles Vaccine Market size was valued at USD 3.5 billion in 2022 and expected to reach USD 14.1 billion by 2029, at a significant CAGR of 13.8% from 2023-2029. Shingles is known as Herpes Zoster which causes a blistering painful rash on the skin which lasts from 2 to 4 weeks. But, for some people, the pain may last for months or years. This pain is called as (PHN) Post Herpetic Neuralgia, which is common complication of shingles and it occurrence increases with age. There are safe and effective vaccines are available for prevention of shingles. In 2006, Merck & Co., Inc. licenced Zostavax for prevention of shingles which is intended for people above 50years of age. In 2016, GSK received FDA approval for its Shingrix, vaccine to prevent shingles which has 90% efficiency in people than zostavax. GSK filed regulatory approvals in Europe, Canada and Japan for Shingrix. Shingles vaccine market is a very high consolidated market with very few market players. It is experiencing a rapid growth due to the new products and it may gain swift in market growth due to the new entrants into the market during the forecast period.
One key aspect contributing to the global market's overall growth is the increasing number of official recommendations to use these vaccinations. Furthermore, the growing number of senior individuals is predicted to fuel an ever-expanding industry. Many firms have spent a significant amount of money on research and development in order to create new shingles vaccines. This also contributes to a rise in the number of new product approvals by the FDA. The dangers linked with the vaccine's side effects, on the other hand, are extremely substantial. Furthermore, in the poor countries, there is a lack of understanding about supply and use of these products. In the years ahead, it is possible to pose a threat to the Shingles Vaccine Market's growth.
Shingles Vaccine Market Summary
Study Period
2023-29
Base Year
2022
CAGR
13.8%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Shingles Vaccine Market Dynamics
Increase in the prevalence and incidence of shingles disease around the world and increase in the global ageing population is expected to enhance the growth of shingles vaccine market across the globe. But, lack of awareness, high cost of the vaccination, unfavourable insurance coverage is major restraints of the global shingles vaccine market.
North-America Got Significant Share
Shingles Vaccine Market Regional Analysis
Global Shingles Vaccine Market is segmented into Latin America, North America, Asia Pacific, The Middle East and Africa and Europe. North America is expected to dominate the market followed by Europe, owing to increase in population and rise in prevalence of shingles among population. While in Europe the market is expected to gain demand due to rise in the therapeutic demand from EU. Asia Pacific shingles vaccine market is expected to exhibit a rapid growth in shingles market due to presence of large untapped market areas and unmet needs especially in emerging economies, rise in health concerns, and increase in per capita income. Due to the limited awareness is the main restraint of the shingles vaccine market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The shingles vaccine market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Shingles Vaccine Market Segmentation
By Product Type
By Application
- Herpes Zoster
- Others
By End User
- Hospitals
- Clinic
- Others
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East and Africa,
Frequently Asked Questions
The Shingles vaccine market size was valued at USD 3.5 billion in 2022.
The key segments covered in the shingles vaccine market are technology, components, application, and end-users.
The Shingles vaccine market key players are Merck& Co., Inc. (U.S.), GlaxoSmithKline plc (UK), Cipla Inc. (India), Pfizer Inc. (U.S.)
| 1. Executive Summary |
| 2. Global Shingles Vaccine Market Introduction |
| 2.1. Global Shingles Vaccine Market Taxonomy |
| 2.2. Global Shingles Vaccine Market Definitions |
| 2.2.1. By Product Type |
| 2.2.2. By Vaccine Type |
| 2.2.3. By Region |
| 3. Global Shingles Vaccine Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Shingles Vaccine Market Dynamic Factors - Impact Analysis |
| 3.6. Impact of COVID-19 on The Market |
| 3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic |
| 3.8. Mapping Market Players Activities |
| 3.9. Recent Key Developments |
| 3.10. Financial Status of the Market Players |
| 3.11. Recent Acquisitions, Collaborations, and Mergers |
| 4. Global Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Shingles Vaccine Market Forecast, By Product Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 5.1. Shingrix |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Zostavax |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. SKYZoster |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Shingles Vaccine Market Forecast, By Vaccine Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 6.1. Recombinant Vaccine |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Live Attenuated Vaccine |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Shingles Vaccine Market Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Distribution Channel, Vaccine Type, and Region, 2023-2029 |
| 8. North America Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 8.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Shingrix |
| 8.1.2. Sheath |
| 8.1.3. SKYZoster |
| 8.1.4. Others |
| 8.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Recombinant Vaccine |
| 8.2.2. Live Attenuated Vaccine |
| 8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. U.S. |
| 8.3.2. Canada |
| 8.4. North America Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2023-2029 |
| 8.5. North America Shingles Vaccine Market Dynamics Trends |
| 9. Europe Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 9.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Shingrix |
| 9.1.2. Sheath |
| 9.1.3. SKYZoster |
| 9.1.4. Others |
| 9.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Recombinant Vaccine |
| 9.2.2. Live Attenuated Vaccine |
| 9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Italy |
| 9.3.5. Spain |
| 9.3.6. Rest of Europe |
| 9.4. Europe Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2023-2029 |
| 9.5. Europe Shingles Vaccine Market Dynamics Trends |
| 10. Asia-Pacific Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 10.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Shingrix |
| 10.1.2. Sheath |
| 10.1.3. SKYZoster |
| 10.1.4. Others |
| 10.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Recombinant Vaccine |
| 10.2.2. Live Attenuated Vaccine |
| 10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Japan |
| 10.3.2. China |
| 10.3.3. India |
| 10.3.4. ASEAN |
| 10.3.5. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2023-2029 |
| 10.5. Asia-Pacific Shingles Vaccine Market Dynamics Trends |
| 11. Latin America Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 11.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Shingrix |
| 11.1.2. Sheath |
| 11.1.3. SKYZoster |
| 11.1.4. Others |
| 11.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Recombinant Vaccine |
| 11.2.2. Live Attenuated Vaccine |
| 11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Argentina |
| 11.3.3. Rest of Latin America |
| 11.4. Latin America Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2023-2029 |
| 11.5. Latin America Shingles Vaccine Market Dynamics Trends |
| 12. Middle East and Africa Shingles Vaccine Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Million) |
| 12.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Shingrix |
| 12.1.2. Sheath |
| 12.1.3. SKYZoster |
| 12.1.4. Others |
| 12.2. Vaccine Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Recombinant Vaccine |
| 12.2.2. Live Attenuated Vaccine |
| 12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Saudi Arabia |
| 12.3.2. GCC Countries |
| 12.3.3. South Africa |
| 12.3.4. Rest of MEA |
| 12.4. MEA Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2023-2029 |
| 12.5. MEA Shingles Vaccine Market Dynamics Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Product Type Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. GlaxoSmithKline plc. |
| 13.2.2. Merck & Co., Inc. |
| 13.2.3. SK chemicals |
| 13.2.4. Green Cross Corp |
| 13.2.5. CanSinoBIO |
| 13.2.6. Geneone Life Science |
| 13.2.7. Vaccitech |
| 13.2.8. Curevo Inc |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
- Merck& Co., Inc. (U.S.)
- GlaxoSmithKline plc (UK)
- Cipla Inc. (India)
- Pfizer Inc. (U.S.)